Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹1.94 (vs ₹1.26 in FY 2025) Full year 2026 results: EPS: ₹1.94 (up from ₹1.26 in FY 2025). Revenue: ₹1.31b (up 60% from FY 2025). Net income: ₹64.0m (up 54% from FY 2025). Profit margin: 4.9% (down from 5.1% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • May 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹297.0m market cap, or US$3.13m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Profit margins are more than 30% lower than last year (4.7% net profit margin). Announcement • Mar 26
JFL Life Sciences Limited has withdrawn its Follow-on Equity Offering in the amount of INR 329.95323 million. JFL Life Sciences Limited has withdrawn its Follow-on Equity Offering in the amount of INR 329.95323 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 32,995,323
Price\Range: INR 10
Transaction Features: Regulation S; Rights Offering New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹461.9m market cap, or US$5.14m). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (4.7% net profit margin). Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹13.35, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 21% over the past three years. Reported Earnings • Nov 13
Second quarter 2026 earnings released: EPS: ₹0.60 (vs ₹0.51 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.60 (up from ₹0.51 in 2Q 2025). Revenue: ₹299.2m (up 22% from 2Q 2025). Net income: ₹19.7m (up 17% from 2Q 2025). Profit margin: 6.6% (down from 6.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Announcement • Nov 06
JFL Life Sciences Limited to Report First Half, 2026 Results on Nov 11, 2025 JFL Life Sciences Limited announced that they will report first half, 2026 results on Nov 11, 2025 Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹14.40, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years. Announcement • Sep 01
JFL Life Sciences Limited, Annual General Meeting, Sep 26, 2025 JFL Life Sciences Limited, Annual General Meeting, Sep 26, 2025, at 11:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹13.40, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total loss to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹16.10, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 18% over the past year. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹21.45, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 59% over the past year. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹19.10, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past year. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹21.30, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 44% over the past year. Valuation Update With 7 Day Price Move • Jan 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹23.90, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past year. New Risk • Jan 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹829.8m (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (₹829.8m market cap, or US$9.59m). Minor Risk Paying a dividend despite having no free cash flows. New Risk • Dec 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹1.09b market cap, or US$12.8m). Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹33.75, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 131% over the past year. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹24.45, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 50% over the past year. New Risk • Sep 20
New minor risk - Dividend sustainability The company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹717.1m market cap, or US$8.58m). Minor Risk Short dividend paying track record (less than a year of continuous dividend payments). Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹66.15, the stock trades at a trailing P/E ratio of 22x. Average trailing P/E is 43x in the Pharmaceuticals industry in India. Total returns to shareholders of 29% over the past year. Announcement • Sep 02
JFL Life Sciences Limited, Annual General Meeting, Sep 23, 2024 JFL Life Sciences Limited, Annual General Meeting, Sep 23, 2024, at 11:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹61.30, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 20% over the past year. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹48.80, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past year. New Risk • May 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹450.9m market cap, or US$5.43m). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). New Risk • Apr 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹494.9m market cap, or US$5.93m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹45.00, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 3.0% over the past year. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past year. Reported Earnings • Nov 14
First half 2024 earnings released: EPS: ₹1.19 (vs ₹1.21 in 1H 2023) First half 2024 results: EPS: ₹1.19. Revenue: ₹207.0m (up 7.5% from 1H 2023). Net income: ₹13.1m (up 31% from 1H 2023). Profit margin: 6.3% (up from 5.2% in 1H 2023). The increase in margin was driven by higher revenue. Announcement • Sep 06
JFL Life Sciences Limited, Annual General Meeting, Sep 27, 2023 JFL Life Sciences Limited, Annual General Meeting, Sep 27, 2023, at 11:30 Indian Standard Time. Agenda: To receive, consider and adopt the Financial Statements of the company which includes Audited Balance Sheet as at March 31, 2023, the Statement of Profit and Loss Account, Cash Flow Statement & Notes forming part of the Financial Statements for the year ended on that date together with the Auditor's Report thereon and Report of the Board of Directors; and to appoint Mr. Manishkumar Jasvantal Patel, who retire by rotation and being eligible, offers himself for re-appointment as Director. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹50.05, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Reported Earnings • Jun 02
Full year 2023 earnings released: EPS: ₹2.90 (vs ₹4.12 in FY 2022) Full year 2023 results: EPS: ₹2.90 (down from ₹4.12 in FY 2022). Revenue: ₹444.7m (up 29% from FY 2022). Net income: ₹28.1m (flat on FY 2022). Profit margin: 6.3% (down from 8.1% in FY 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹40.90, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 24% share price gain to ₹42.15, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Announcement • Sep 08
JFL Life Sciences Limited has completed an IPO in the amount of INR 181.658 million. JFL Life Sciences Limited has completed an IPO in the amount of INR 181.658 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 1,414,000
Price\Range: INR 61
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 1,564,000
Price\Range: INR 61
Transaction Features: Regulation S 
